# A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

> **NCT03862846** · PHASE1 · TERMINATED · sponsor: **Reneo Pharma Ltd** · enrollment: 23 (actual)

## Conditions studied

- Primary Mitochondrial Myopathy

## Interventions

- **DRUG:** REN001

## Key facts

- **NCT ID:** NCT03862846
- **Lead sponsor:** Reneo Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-10
- **Primary completion:** 2020-04-23
- **Final completion:** 2020-04-23
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** COVID-19 Pandemic sufficient data gathered to achieve the study objective
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862846, "A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03862846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*